Lonza acquires UCB-Bioprods for 120M euros

Switzerland-based custom peptide manufacturer Lonza says it completed its acquisition of Brussels, Belgium-based UCB-Bioproducts on 28 February, this year. Lonza bought the Dutch drugmaker's peptide manufacturing division for 120.0 million euros.

The unit, which has approximately 300 employees, is located in Braine-l'Alleud just outside the Belgian capital and Lonza say that, by uniting the two peptide businesses, it has become the leading and sole contract manufacturer with a "historically-successful track record" of providing Active Pharmaceutical Ingredients from any of the three peptide technologies: liquid phase peptide synthesis, solid phase peptide synthesis and recombinant technology.

Benefits of expanded reach